{
  "documentMetadata": {
    "title": "Acute Urinary Tract Infection in Children Age >= 2 Months",
    "sourceFile": "UTI, Acute, Child, Age &ge_ 2 months.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Acute urinary tract infection (UTI) in children age â‰¥ 2 months.",
        "Diagnosis should be based on abnormal UA (WBC, leukocyte esterase or nitrite) AND >50,000 cfu/mL of a urinary pathogen)",
        "Culture of bagged urine specimens are not reliable and should not be used. Bagged specimens can be used for UA",
        "Clean catch mid void specimen in older children and adolescents may be acceptable if it can be reliably obtained",
        "Blood cultures should be obtained in toxic appearing young children",
        "Flank pain, persistent fevers, and other systemic symptoms may suggest upper tract disease"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Enteric bacteria (E. coli, Klebsiella, Enterobacter, Citrobacter), Enterococcus sp."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "IV therapy may be preferred for seriously ill children or those who cannot take oral therapy. Oral therapy generally equally effective",
        "Empiric therapy should be based on local susceptibility patterns"
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "IV therapy options for empiric use:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Ceftriaxone",
                "dose": "75-100 mg/kg",
                "route": "IV",
                "frequency": "once daily"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Ceftazidime",
                "dose": "50 mg/kg",
                "route": "IV",
                "frequency": "q8h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "condition": "where available",
            "components": [
              {
                "drug": "Cefotaxime",
                "dose": "50 mg/kg",
                "route": "IV",
                "frequency": "q8h"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Oral options:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Amoxicillin-clavulanate",
                "dose": "10-15 mg/kg",
                "route": "po",
                "frequency": "q8h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Cephalexin",
                "dose": "50-100 mg/kg/day",
                "route": "po",
                "frequency": "divided q8h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "TMP-SMX",
                "dose": "6-12 mg/kg/day TMP component",
                "route": "po",
                "frequency": "divided q12h"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Cefixime",
                "dose": "8 mg/kg",
                "route": "po",
                "frequency": "once daily"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Recommended",
            "components": [
              {
                "drug": "Cefpodoxime",
                "dose": "10 mg/kg/day",
                "frequency": "divided q12h"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Alternative",
        "components": [
          {
            "drug": "Ciprofloxacin",
            "dose": "20-30 mg/kg in 2 divided doses to maximum dose of 1500 mg per day"
          }
        ]
      }
    },
    {
      "type": "crossReference",
      "referenceData": {
        "text": "For ESBL and other resistant organisms, see Overview of Resistant Gram Negative Organisms",
        "targetType": "internalDocument",
        "targetIdentifier": "Overview of Resistant Gram Negative Organisms"
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Normal urinalysis of fresh urine specimen reasonably excludes UTI",
        "Do not treat asymptomatic bacteriuria",
        "Narrow therapy once susceptibility is known",
        "5 day course non-inferior to 10 day course although trial may not be fully applicable to pyelonephritis (Pediatrics an 1;153(1):e2023062598 2024)",
        "Switch to oral therapy when improving and able to tolerate oral therapy. Post pubertal girls can be treated as for adult women"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Obtain renal ultrasound within 6 weeks for first UTI in children < 24 months old. Obtain immediately if severely ill",
        "For children >24 months, obtain renal ultrasound if recurrent or atypical UTI",
        "Voiding cystourethrogram (VCUG) is no longer routinely recommended unless ultrasound shows hydronephrosis, evidence suggesting severe reflux or obstruction",
        "Ciprofloxacin is not FDA-approved for uncomplicated UTIs in persons age < 18 years (it is approved for complicated UTIs in that age group).",
        "See Pediatrics 128:595, 2011 for discussion of management guidelines and when to consider prophylaxis for recurrent UTI."
      ]
    }
  ]
}